Download video

The clinical trial process

No views

Association of the British Pharmaceutical Industry

1 day ago

The clinical trial process

The clinical trial process

What Are The Risks Of Secondary Cancers With Chronic Lymphocytic Leukemia? - Leukemia Wellness Guide
3:25
What Are The Risks Of Secondary Cancers With Chronic Lymphocytic Leukemia? - Leukemia Wellness Guide
by Leukemia Wellness Guide
Looking Ahead: Gaps, Hurdles, and Transition in Current Phase 2 RLT Trial Landscape
7:24
Looking Ahead: Gaps, Hurdles, and Transition in Current Phase 2 RLT Trial Landscape
by GU Oncology Now
Part 2. Along the way to failure of GBR : Clinical Aspects
27:19
Part 2. Along the way to failure of GBR : Clinical Aspects
by Purgo Biologics Inc.
A New Paradigm in the Detection of Amyloid Pathology: The Emergence of Highly Accurate Blood Tests
1:00:22
A New Paradigm in the Detection of Amyloid Pathology: The Emergence of Highly Accurate Blood Tests
by C2N Diagnostics
Adherence Matters: The Key to Optimizing Clinical Outcomes 20\/3\/25, 1pm CEST (Final Announcement)
0:54
Adherence Matters: The Key to Optimizing Clinical Outcomes 20\/3\/25, 1pm CEST (Final Announcement)
by P2PMD
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
[Trailer] ACT-T2D Episode 1: Early optimal glycemic control to prevent T2D complications
1:14
[Trailer] ACT-T2D Episode 1: Early optimal glycemic control to prevent T2D complications
by P2PMD
A Phase II trial of venetoclax and cytarabine with or without midostaurin in older patients with AML
4:27
A Phase II trial of venetoclax and cytarabine with or without midostaurin in older patients with AML
by VJHemOnc – Video Journal of Hematology \& HemOnc
What’s New in Chronic Lymphocytic Leukemia (CLL)?
34:35
What’s New in Chronic Lymphocytic Leukemia (CLL)?
by Blood Cancer United
Acalabrutinib vs. Ibrutinib for Treatment of Chronic Lymphocytic Leukemia (CLL) - Dr. Lindsey Roeker
12:09
Acalabrutinib vs. Ibrutinib for Treatment of Chronic Lymphocytic Leukemia (CLL) - Dr. Lindsey Roeker
by CLL Society
Venetoclax for Multiple Myeloma in the Post-CANOVA Era: Rahul Banerjee, MD, FACP, and Andrew Yee, MD
20:12
Venetoclax for Multiple Myeloma in the Post-CANOVA Era: Rahul Banerjee, MD, FACP, and Andrew Yee, MD
by Oncology Data Advisor
Insights into the Phase II WINDOW-2 trial
0:50
Insights into the Phase II WINDOW-2 trial
by VJHemOnc – Video Journal of Hematology \& HemOnc
【Key Message】Early Optimal Control of Glycemia Level is Crucial in Preventing T2D Complications
10:52
【Key Message】Early Optimal Control of Glycemia Level is Crucial in Preventing T2D Complications
by P2PMD
The Road to a Successful Inspection - What’s Being Inspected and Why It Matters - Part 2
17:26
The Road to a Successful Inspection - What’s Being Inspected and Why It Matters - Part 2
by GCP-Mindset - All About Clinical Research
RESPROJ2 Evidence Based Medicine Critical Appraisal of Literature Therapy or Prevention 09 30 25
10:57
RESPROJ2 Evidence Based Medicine Critical Appraisal of Literature Therapy or Prevention 09 30 25
by UERM Medicine Batch 2027C
How to Appraise a Clinical Trial - Part 2
25:43
How to Appraise a Clinical Trial - Part 2
by Strong Medicine
2B | A MyCancerHaven™ Expert Roundtable:The Evolution of MM: Selecting Treatment After 3rd Relapse
28:28
2B | A MyCancerHaven™ Expert Roundtable:The Evolution of MM: Selecting Treatment After 3rd Relapse
by MyCancerHaven for Patients \& Caregivers
Reducing Risk - Impact of complaints - Part 2
42:49
Reducing Risk - Impact of complaints - Part 2
by Medical Protection
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Brea...
32:07
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Brea...
by Medscape
[Trailer] Multimorbidity \& Risk Factors: Should we shape again the CV continuum (20-2-2025, 1pm CET)
0:53
[Trailer] Multimorbidity \& Risk Factors: Should we shape again the CV continuum (20-2-2025, 1pm CET)
by P2PMD